SXTP
60 Degrees Pharmaceuticals Inc
$
1.300
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.315
Open
1.310
VWAP
1.25
Vol
56.84K
Mkt Cap
3.28M
Low
1.220
Amount
71.31K
EV/EBITDA(TTM)
--
Total Shares
12.21M
EV
9.24M
EV/OCF(TTM)
--
P/S(TTM)
1.92
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
400.00K
+65.54%
-1.340
-84.2%
400.00K
+195.66%
-1.380
-68.19%
300.00K
+140.06%
-1.280
-93.77%
Estimates Revision
The market is revising No Change the revenue expectations for 60 Degrees Pharmaceuticals, Inc. (SXTP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -3.35%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-3.35%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is 3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 1.300
Low
3.40
Averages
3.40
High
3.40
Current: 1.300
Low
3.40
Averages
3.40
High
3.40
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-28
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-03-28
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-01-10
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-01-10
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2024-12-23
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2024-12-23
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2024-12-11
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2024-12-11
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2024-11-15
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2024-11-15
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP.O) is -0.59, compared to its 5-year average forward P/E of -0.88. For a more detailed relative valuation and DCF analysis to assess 60 Degrees Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.88
Current PE
-0.59
Overvalued PE
-0.02
Undervalued PE
-1.74
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
4.85
Current PS
2.65
Overvalued PS
10.60
Undervalued PS
-0.91
Financials
Annual
Quarterly
FY2025Q1
YoY :
+75.42%
256.28K
Total Revenue
FY2025Q1
YoY :
+43.50%
-1.91M
Operating Profit
FY2025Q1
YoY :
-538.64%
-1.88M
Net Income after Tax
FY2025Q1
YoY :
-183.78%
-1.55
EPS - Diluted
FY2025Q1
YoY :
+39.35%
-1.60M
Free Cash Flow
FY2025Q1
YoY :
+29.34%
71.41
Gross Profit Margin - %
FY2025Q1
YoY :
-44.35%
-793.62
FCF Margin - %
FY2025Q1
YoY :
-350.05%
-732.51
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
14.4K
USD
Months
6-9
0
0.0
USD
Months
0-12
6
111.2K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
1
14.4K
USD
Months
6-9
0
0.0
USD
Months
0-12
6
111.2K
USD
Months
SXTP News & Events
Events Timeline
2025-10-15 (ET)
2025-10-15
07:17:05
60 Degrees Reports First Patient Successfully Completes Babesiosis Trial Regimen
2025-10-09 (ET)
2025-10-09
07:06:19
60 Degrees Pharmaceuticals Reveals Name for Chronic Babesiosis Study
2025-08-19 (ET)
2025-08-19
08:59:09
60 Degrees Chooses Icahn School of Medicine as Main Location for Phase II Trial
Sign Up For More Events
Sign Up For More Events
News
9.0
10-09Newsfilter60 Degrees Pharmaceuticals Reveals Name of Clinical Trial for Chronic Babesiosis: B-FREE Study
4.0
09-03BenzingaAlphabet Set to Surge by 23%? Check Out 10 Leading Analyst Predictions for Wednesday
4.0
09-03BenzingaAscendiant Capital Reaffirms Buy Rating on 60 Degrees, Adjusts Price Target to $3
Sign Up For More News
People Also Watch
FAQ
What is 60 Degrees Pharmaceuticals Inc (SXTP) stock price today?
The current price of SXTP is 1.3 USD — it has increased 0 % in the last trading day.
What is 60 Degrees Pharmaceuticals Inc (SXTP)'s business?
What is the price predicton of SXTP Stock?
What is 60 Degrees Pharmaceuticals Inc (SXTP)'s revenue for the last quarter?
What is 60 Degrees Pharmaceuticals Inc (SXTP)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for 60 Degrees Pharmaceuticals Inc (SXTP)'s fundamentals?
How many employees does 60 Degrees Pharmaceuticals Inc (SXTP). have?